News

Media Report

Third-party coverage of IASO Biotechnology.

Categories

IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma

IASO Bio’s CD20-targeted in vivo CAR-T cleared for US study in B-NHL

GC Cell introduces multiple myeloma CAR-T therapy from China's IASO Biotech

IASO Bio's Equecabtagene Autoleucel Gains First Approval Outside Mainland China

Macau approves IASO Bio's multiple myeloma therapy